Market Overview:
The global uveitis treatment market size reached US$ 1.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2027, exhibiting a CAGR of 5.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of eye and sensitivity to light. Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines. These therapeutics are directed toward reducing inflammation, alleviating pain, preventing further tissue damage and restoring vision loss and can be used to treat conditions, including anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.
The increasing prevalence of optical infections and chronic eye disorders across the globe represents one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy and autoimmune and inflammatory disorders. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness regarding the available treatment alternatives for managing uveitis has resulted in a significant increase in the demand for corticosteroid treatments among patients and healthcare providers. Additionally, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors. These biological therapeutic agents are effective in the treatment of chronic uveitis and are administered as subcutaneous injections. Other factors, including the implementation of favorable initiatives by the governments to promote public health, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global uveitis treatment market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on treatment type, disease type, cause and distribution channel.
Breakup by Treatment Type:
- Corticosteroids
- Immunosuppressant
- Monoclonal Antibodies
- Cycloplegic Agents
- Antibiotics
- Antivirals
- Antifungal
- Analgesics
Breakup by Disease Type:
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
Breakup by Cause:
- Infectious
- Non-infectious
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Treatment Type, Disease Type, Cause, Distribution Channel, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global uveitis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global uveitis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the disease type?
- What is the breakup of the market based on the cause?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global uveitis treatment market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Uveitis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Corticosteroids
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Immunosuppressant
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Monoclonal Antibodies
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Cycloplegic Agents
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Antibiotics
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Antivirals
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Antifungal
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Analgesics
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Disease Type
7.1 Anterior Uveitis
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Posterior Uveitis
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Intermediate Uveitis
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Panuveitis
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Cause
8.1 Infectious
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Non-infectious
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 AbbVie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Alimera Sciences Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.3 Bausch & Lomb Incorporated (Bausch Health)
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.4 Enzo Biochem Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Eyegate Pharmaceuticals Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Eyepoint pharmaceuticals Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.7 Novartis AG
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Regeneron Pharmaceuticals Inc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Santen Pharmaceutical Co. Ltd.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
List of Figures
Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2021
Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2021
Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2021
Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2021
Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: China: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: India: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: France: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
Figure 95: Global: Uveitis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2022-2027
Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2022-2027
Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million US$), 2022-2027
Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Uveitis Treatment Market Structure
Table 8: Global: Uveitis Treatment Market: Key Players